Literature DB >> 2364393

Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

L Schweigerer1, S Breit, A Wenzel, K Tsunamoto, R Ludwig, M Schwab.   

Abstract

Amplification and enhanced expression of the MYCN oncogene are thought to contribute to the development and progression of human neuroblastomas. Here, we have transfected human neuroblastoma cells that harbor a single MYCN gene copy with the human MYCN gene driven by a viral enhancer/promoter, and we have compared the properties of the parental and the transfected cells. The transfected cells show an enhanced expression of the exogenous MYCN gene. Unlike the parental cells, they have acquired an increased proliferative potential, induce tumors in nude mice, grow in soft agar, and require low amounts of exogenous growth factors in order to proliferate. The MYCN-transfected, but not the parental, cells can synthesize and utilize autocrine growth factor activity. These results demonstrate that enhanced MYCN expression contributes to malignant progression of human neuroblastoma cells, conceivably by stimulating the expression of autocrine growth factor activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364393

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Neuroblastoma as a neurobiological disease.

Authors:  N F Schor
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma.

Authors:  Raoud Marayati; Adele P Williams; Laura V Bownes; Colin H Quinn; Jerry E Stewart; Elizabeth Mroczek-Musulman; Venkatram R Atigadda; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2020-02-28       Impact factor: 2.545

4.  Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2015-05-05       Impact factor: 6.261

Review 5.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

6.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Authors:  Louis Chesler; Chris Schlieve; David D Goldenberg; Anna Kenney; Grace Kim; Alex McMillan; Katherine K Matthay; David Rowitch; William A Weiss
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

7.  MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.

Authors:  Hsiu-Hao Chang; Yu-Fen Tseng; Meng-Yao Lu; Yung-Li Yang; Shu-Wei Chou; Dong-Tsamn Lin; Kai-Hsin Lin; Shiann-Tarng Jou; Wen-Ming Hsu; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

Review 8.  Targeting focal adhesion kinase in neuroblastoma.

Authors:  Lauren Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

9.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis.

Authors:  T Fotsis; M Pepper; H Adlercreutz; G Fleischmann; T Hase; R Montesano; L Schweigerer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.

Authors:  Michael L Megison; Jerry E Stewart; Hugh C Nabers; Lauren A Gillory; Elizabeth A Beierle
Journal:  Clin Exp Metastasis       Date:  2012-12-04       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.